Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

What the trial testedrandomised · 376 people · 2026

Randomised comparison

+25.5percentage points+14.5 to +36.5

As reported

difference 25.5 %, 95% CI 14.5–36.5

Randomised comparison

+41.7+24.4 to +59.0

As reported

difference 41.7, 95% CI 24.4–59.0

the abstract, start to end

… an estimated treatment difference of MBE 25.5% (95% confidence interval 14.5 …

… an estimated treatment difference of MBE 41.7 (95% confidence interval 24.4 …

← favours treatmentfavours comparator →

could be chance

Body weight & composition

25.514.5–36.5

Body weight & composition

41.724.4–59.0

Investigational compoundsBody weight & composition

Investigational compounds × body weight & compositionhelps?settled

unlikelylikely

1.001.00 without it

← favours comparatorfavours treatment →

this papermore certainless certain

1 / 5

2026

this papercites it